HAb18G/CD147, ITS ANTAGONIST AND APPLICATION

摘要

A liver cancer tissue-originated protein molecule HAb18G/CD147 capable of promoting tumor metastasis, is new. It is encoded by a gene sequence homologous with that of the leukocyte differentiation antigen CD147 and is a member of the CD147 family, isolated e.g. by using liver cancer-specific monoclonal antibody HAb18G affinity chromatography. Independent claims are also included for the following: (1) an expression plasmid vector antisense nucleotide PCI-neo/as HAb18G of the protein molecule, constructed by ligating the HAb18G/CD147 cDNA full-length antisense nucleotide to a eukaryote expression vector PCI-neo which is an antisense RNA plasmid vector that can inhibit translation of the HAb18G/CD147 mRNA; (2) HAb18G/CD147 peptide antagonists containing one of 9 12 residue amino acid sequences, given in the specification; (3) prevention and therapy of tumor recurrence or metastasis, rheumatoid arthritis, osteoarthritis, human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), arteriosclerosis, ectatic mycocardiopathy by administering an effective dose of the expression plasmid of the antisense nucleotide, or the peptide antagonists or their mixture; and (4) drug compositions for preventing and treating the diseases containing the expression plasmid of the antisense nucleotide or/and peptide antagonists, and pharmaceutically-acceptable carrier. ACTIVITY : Cytostatic; Antirheumatic; Antiarthritic; Anti-HIV; Antiarteriosclerotic; Cardiant. No biological data is given. MECHANISM OF ACTION : Antisense gene therapy.